Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025Exploring partnership ...

For organizations wishing to embed AI ethics into the organization, a hub-and-spoke model is proving to be the nascent “gold ...